Additional InformationGBI Research, the leading business intelligence provider has released its latest research Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns, which essentially provides insights on lifestyle disorders therapeutics sales and price forecasts until 2016. The report also examines the global lifestyle disorders therapies treatment usage patterns. In addition, the geographical distribution of lifestyle disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the lifestyle disorders Research and Development (R&D) pipeline and the potential future blockbusters up to 2016. The report provides an in-depth analysis of the top five lifestyle disorders therapeutic indications, which are erectile dysfunction, obesity, alopecia, smoking cessation and alcohol dependence. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving lifestyle disorders therapies is also presented.
It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.
Erectile Dysfunction Therapeutics Market is Dominated by Late Stage Pipeline Molecules
The Erectile Dysfunction (ED) therapeutics market pipeline has five molecules in the late stages of development. Some of these molecules are Avanafil, Udenafil and TA-1790, me-too molecules by their mechanism of action. They belong to the phosphodiesterase type 5 inhibitors class and are expected to be launched in the near future. Other Phase III candidates such as Alfuzosin and Vitaros are first-in-class molecules. Launch of these molecules will support the markets growth.
The Anti-obesity Market has Huge Unmet Needs Due to Less Efficacious Marketed Drugs and a Poor Therapeutics Pipeline
The anti-obesity drug market is very low. The main factors responsible for the low sales record are the poor efficacy and safety profiles of the marketed drugs and the availability of other safe treatment options. Drugs such as Acomplia were pulled out of the European market due to potential side effects, including psychiatric problems such as depression, anxiety and stress disorders. In 2009, the global anti-obesity drugs market was estimated at $1.4 billion, indicating a CAGR of 12.8% between 2002 and 2009. The growth rate might depict a healthy sales growth; however, since the value in 2002 was very small, the market growth registered a double digit growth. The only major drugs in the market are orlistat and sibutramine. Generics and OTC drugs account for a significant share in the anti-obesity drug market. Xenical leads the global anti-obesity market. With no major molecules in the pipeline, the market is forecast to register a modest growth of 12.2% between 2009 and 2016 and record sales worth $3.1 billion.
Global Obesity Therapeutics Market, Global, Revenue ($bn), 2002-2016
Source: GBI Research
Discontinuation of Development, Health Risk Issues and Concerns Regarding Pricing of Lifestyle Disorders Products Will Impede Growth
Recent years have seen quite a few discontinuations of products in this sector. One of the major instances of this was Sanofi-aventis terminating the development of its smoking cessation product Dianicline, citing as its reasons that it was not differentiated adequately from Chantix.. In July 2009, the FDA had added a black box label warning on neuropsychiatric effects to the Chantix and Zyban labels, which is likely to impede their growth over the forecast period.
Roches Xenical and GSKs Alli are also being reviewed by the US FDA for risks of liver injury. Over the period 1999 to October 2008, the FDA had received 32 reports on cases of serious liver injury in orlistat patients.
The Swiss units of the leading firms, Bayer, Eli Lilly and Pfizer were fined in December 2009 by the Swiss Competition Commission over the issue of price fixing of erectile dysfunction drugs, Levitra (vardenafil), Cialism (tadalafil) and Viagra (sildenafil). The commission claimed that the companies fixed drug prices through public price recommendations.
Shortage of Major Alternate Therapies Other Than Vivitrol is a Major Concern for the Alcohol Dependence Market
The market is estimated to reach revenues of approximately $348m by 2016, growing at a CAGR of 15.9% between 2009 and 2016. The growth shall be driven primarily by a few major products which are expected to be launched during the forecast period.
The launch of two opioid antagonists is predicted for 2011; BioTie's Nalmefene and Elbion's Naltrel. Nalmefene is a major product, and its anticipated lack of requiring alcohol abstinence prior to treatment and 'as-needed' dosing regimen will make the drug an attractive treatment option for patients. However, based on mediocre clinical data to date, the drug is not expected to overtake Vivitrol's prescription sales.
The market shall also be driven significantly by increased patient awareness, leading to a higher treatment seeking rate and better compliance and persistence towards the various therapies
More Smoking Cessation reports by GBI Research
See all reports like this >>
Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge by GBI Research
Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a ChallengeSummaryGBI Research, a leading ...